Needham analyst Michael Matson maintained a Buy rating on Haemonetics today and set a price target of $78.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Michael Matson has given his Buy rating due to a combination of factors including Haemonetics’ recent financial performance and future outlook. The company exceeded expectations in both revenue and earnings per share for the second quarter of fiscal year 2026, prompting an upward revision of its financial guidance. Despite a slight decline in organic growth, Haemonetics showed strong performance in plasma sales excluding CSL, which increased significantly.
Additionally, the company’s margins have improved, with a notable increase in both gross and operating margins compared to the previous year. These financial improvements, along with the company’s strategic adjustments and conservative guidance for hospital operations, have led to an increased price target, reflecting confidence in Haemonetics’ potential for continued growth.
In another report released today, BTIG also reiterated a Buy rating on the stock with a $88.00 price target.